1. Home
  2. COGT vs ULH Comparison

COGT vs ULH Comparison

Compare COGT & ULH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • ULH
  • Stock Information
  • Founded
  • COGT 2014
  • ULH 1932
  • Country
  • COGT United States
  • ULH United States
  • Employees
  • COGT N/A
  • ULH N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • ULH Trucking Freight/Courier Services
  • Sector
  • COGT Health Care
  • ULH Industrials
  • Exchange
  • COGT Nasdaq
  • ULH Nasdaq
  • Market Cap
  • COGT 1.0B
  • ULH 1.2B
  • IPO Year
  • COGT 2018
  • ULH 2005
  • Fundamental
  • Price
  • COGT $8.00
  • ULH $27.59
  • Analyst Decision
  • COGT Buy
  • ULH Hold
  • Analyst Count
  • COGT 6
  • ULH 1
  • Target Price
  • COGT $14.17
  • ULH $44.00
  • AVG Volume (30 Days)
  • COGT 1.3M
  • ULH 62.4K
  • Earning Date
  • COGT 03-04-2025
  • ULH 02-06-2025
  • Dividend Yield
  • COGT N/A
  • ULH 1.53%
  • EPS Growth
  • COGT N/A
  • ULH 39.66
  • EPS
  • COGT N/A
  • ULH 4.93
  • Revenue
  • COGT N/A
  • ULH $1,846,035,000.00
  • Revenue This Year
  • COGT N/A
  • ULH N/A
  • Revenue Next Year
  • COGT N/A
  • ULH $7.92
  • P/E Ratio
  • COGT N/A
  • ULH $5.57
  • Revenue Growth
  • COGT N/A
  • ULH 11.06
  • 52 Week Low
  • COGT $5.73
  • ULH $27.19
  • 52 Week High
  • COGT $12.61
  • ULH $53.29
  • Technical
  • Relative Strength Index (RSI)
  • COGT 41.50
  • ULH 20.74
  • Support Level
  • COGT $7.88
  • ULH $28.01
  • Resistance Level
  • COGT $8.37
  • ULH $31.25
  • Average True Range (ATR)
  • COGT 0.42
  • ULH 2.29
  • MACD
  • COGT -0.11
  • ULH -0.85
  • Stochastic Oscillator
  • COGT 5.85
  • ULH 2.29

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

About ULH Universal Logistics Holdings Inc.

Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.

Share on Social Networks: